TY - JOUR
T1 - LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease
T2 - The NUDAD project
AU - de Leeuw, Francisca A.
AU - Tijms, Betty M.
AU - Doorduijn, Astrid S.
AU - Hendriksen, Heleen M.A.
AU - van de Rest, Ondine
AU - de van der Schueren, Marian A.E.
AU - Visser, Marjolein
AU - van den Heuvel, Ellen G.H.M.
AU - van Wijk, Nick
AU - Bierau, Jörgen
AU - van Berckel, Bart N.
AU - Scheltens, Philip
AU - Kester, Maartje I.
AU - van der Flier, Wiesje M.
AU - Teunissen, Charlotte E.
PY - 2020/12/30
Y1 - 2020/12/30
N2 - INTRODUCTION: We examined associations between nutritional biomarkers and clinical progression in individuals with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and Alzheimer's disease (AD)-type dementia. METHODS: We included 528 individuals (64 ± 8 years, 46% F, follow-up 2.1 ± 0.87 years) with SCD (n = 204), MCI (n = 130), and AD (n = 194). Baseline levels of cholesterol, triglycerides, glucose, homocysteine, folate, vitamin A, B12, E and uridine were measured in blood and S-adenosylmethionine and S-adenosylhomocysteine in cerebrospinal fluid. We determined associations between nutritional biomarkers and clinical progression using Cox proportional hazard models. RESULTS: Twenty-two (11%) patients with SCD, 45 (35%) patients with MCI, and 100 (52%) patients with AD showed clinical progression. In SCD, higher levels of low-density lipoprotein (LDL) cholesterol were associated with progression (hazard ratio [HR] [95% confidence interval (CI)] 1.88 [1.04 to 3.41]). In AD, lower uridine levels were associated with progression (0.79 [0.63 to 0.99]). DISCUSSION: Our findings suggest that LDL cholesterol and uridine play a—stage-dependent—role in the clinical progression of AD.
AB - INTRODUCTION: We examined associations between nutritional biomarkers and clinical progression in individuals with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and Alzheimer's disease (AD)-type dementia. METHODS: We included 528 individuals (64 ± 8 years, 46% F, follow-up 2.1 ± 0.87 years) with SCD (n = 204), MCI (n = 130), and AD (n = 194). Baseline levels of cholesterol, triglycerides, glucose, homocysteine, folate, vitamin A, B12, E and uridine were measured in blood and S-adenosylmethionine and S-adenosylhomocysteine in cerebrospinal fluid. We determined associations between nutritional biomarkers and clinical progression using Cox proportional hazard models. RESULTS: Twenty-two (11%) patients with SCD, 45 (35%) patients with MCI, and 100 (52%) patients with AD showed clinical progression. In SCD, higher levels of low-density lipoprotein (LDL) cholesterol were associated with progression (hazard ratio [HR] [95% confidence interval (CI)] 1.88 [1.04 to 3.41]). In AD, lower uridine levels were associated with progression (0.79 [0.63 to 0.99]). DISCUSSION: Our findings suggest that LDL cholesterol and uridine play a—stage-dependent—role in the clinical progression of AD.
KW - Alzheimer's disease
KW - cholesterol
KW - clinical progression
KW - memory clinic
KW - nutritional biomarkers
KW - uridine
U2 - 10.1002/dad2.12120
DO - 10.1002/dad2.12120
M3 - Article
AN - SCOPUS:85100497203
SN - 2352-8729
VL - 12
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
M1 - e12120
ER -